NCT03696680: Stereotactic Radiotherapy for Cerebral Metastases With Recent Hemorrhagic Signal

NCT03696680
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Brain metastases must be suitable for stereotactic radiotherapy; Patient must have extracranial disease that has had a partial response to treatments or has been stable for more than 3 months
Exclusions: Patients with leptomeningeal or brainstem metastasis; Patients with more than 4 brain metastases (Patients who have had a metastasectomy & 1-3 brain lesions are eligible); Patients with a history of whole brain radiotherapy (WBRT)
https://ClinicalTrials.gov/show/NCT03696680

Comments are closed.

Up ↑